Proteina
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Proteina maps how proteins interact with each other inside living cells, information that drug researchers use to identify disease targets and design new medicines.
Its proprietary SPID platform detects and measures these protein-protein interactions (PPIs) at the level of individual molecules, without requiring prior purification of samples, and at high speed and volume. Listed on KOSDAQ, Korea's tech-focused small-cap board, the company packages this capability into two commercial service lines, PPI Landscape®, focused on antibody drug design, and PPI PathFinder®, which supports clinical-stage efficiency for multinational pharmaceutical companies.
Summary is AI-generated and may contain errors · figures from DART filings
Proteina in five facts
What does Proteina do?
Proteina maps how proteins interact with each other inside living cells, information that drug researchers use to identify disease targets and design new medicines.
Where is Proteina listed and in which sector?
Proteina (Korean name: 프로티나) trades under KRX code 468530 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is Proteina?
Its market capitalisation was US$385.6M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Proteina's latest annual revenue and operating profit?
For fiscal year 2025, Proteina reported revenue of US$2.2M, an operating loss of US$8.6M and a net loss of US$6.8M, per its annual report on DART (data retrieved from DART on 2026-06-04).
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-06-04
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Decision to acquire shares/equity in another company
Proteina disclosed an acquisition of ABX Biosciences Co., Ltd., worth US$2.3M.
M&A · Jul 14 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Proteina reported separate results for FY2025: revenue of US$2.01M (+28.2% year on year), an operating loss of US$7.73M and a net loss of US$6.13M.
Earnings · Mar 13